dexfenfluramine has been researched along with sr141716 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Mukherjee, M; Robertson, K; Rowland, NE | 1 |
| Avorn, J | 1 |
| Jones, D | 1 |
| Raffa, RB; Ward, SJ | 1 |
| Bedros, JR; Medvegy, M; Pados, G; Simonyi, G | 1 |
2 review(s) available for dexfenfluramine and sr141716
| Article | Year |
|---|---|
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Dexfenfluramine; Drug Design; Drug Inverse Agonism; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Receptor Agonists | 2011 |
[The pharmacological treatment of obesity: past, present and future].
Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones | 2012 |
4 other study(ies) available for dexfenfluramine and sr141716
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats.
Topics: Animals; Dexfenfluramine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Eating; Female; Male; Naloxone; Narcotic Antagonists; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Serotonin Receptor Agonists | 2001 |
FDA standards--good enough for government work?
Topics: Cannabinoids; Dexfenfluramine; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Sleep Initiation and Maintenance Disorders; United States; United States Food and Drug Administration | 2005 |
End of the line for cannabinoid receptor 1 as an anti-obesity target?
Topics: Anti-Obesity Agents; Cannabinoid Receptor Modulators; Dexfenfluramine; Eating; Humans; Life Style; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Risk Assessment; Risk Factors | 2008 |